Yoshiko Iwai

发表

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

T. Okazaki, T. Honjo, S. Fagarasan, 2013, Nature Immunology.

New regulatory co-receptors: inducible co-stimulator and PD-1.

T. Okazaki, T. Honjo, Yoshiko Iwai, 2002, Current opinion in immunology.

Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1

A. Panoskaltsis-Mortari, B. Blazar, Yoshiko Iwai, 2003, The Journal of Immunology.

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Tasuku Honjo, Yoshiko Iwai, T. Honjo, 2004, Cancer Research.

PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

T. Okazaki, T. Honjo, Yoshiko Iwai, 2003, The Journal of experimental medicine.

Basic leucine zipper transcription factor, ATF-like (BATF) regulates epigenetically and energetically effector CD8 T-cell differentiation via Sirt1 expression

K. Sakimura, H. Takayanagi, Yoshiko Iwai, 2011, Proceedings of the National Academy of Sciences.

Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

G. Freeman, Yoshimasa Tanaka, T. Okazaki, 2002, Immunology letters.

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

T. Honjo, Yoshiko Iwai, S. Terawaki, 2004, International immunology.

Targeting the Chemokine System in Rheumatoid Arthritis and Vasculitis

A. Luster, Yoshiko Iwai, Yoshishige Miyabe, 2020, JMA journal.

Necessity of lysophosphatidic acid receptor 1 for development of arthritis.

H. Ovaa, H. Ueda, J. Chun, 2013, Arthritis and rheumatism.

Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice

R. Steinman, Irene Jarchum, T. Hanafusa, 2008, Proceedings of the National Academy of Sciences.

The regulation of PD-1/PD-L1 pathway and autoimmune diseases

T. Okazaki, T. Honjo, Yoshiko Iwai, 2001 .

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data

G. Höfler, G. Zlabinger, P. Steinberger, 2015 .

Development of Cancer Immunotherapy Targeting the PD-1 Pathway.

Alexander M. Wolf, Yoshiko Iwai, N. Kamimura, 2019, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

Immunotherapy Targeting the PD-1 Signaling Pathway

Yoshiko Iwai, 2016 .

Microanatomical localization of PD-1 in human tonsils.

T. Okazaki, T. Honjo, Yoshiko Iwai, 2002, Immunology letters.

Role of WNT10A-Expressing Kidney Fibroblasts in Acute Interstitial Nephritis

H. Izumi, K. Kohno, Y. Otsuji, 2014, PloS one.

CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid.

T. Honjo, M. Kurosaka, R. Saura, 2003, The Journal of rheumatology.

-Dependent Mechanism g by an IFN-Lethality Accelerates Graft-Versus-Host Disease Blockade of Programmed Death-1 Engagement

B. Blazar, Yoshiko Iwai, B. Carreno, 2003 .

Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid–lysophosphatidic acid receptor 1 cascade

N. Miyasaka, M. Miyasaka, Yoshiko Iwai, 2014, Arthritis Research & Therapy.

IkBfregulatesT H 17developmentbycooperatingwith ROR nuclear receptors

S. Akira, T. Morio, Masahiro Yamamoto, 2010 .

Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.

T. Komori, S. Maeda, Yoshimasa Tanaka, 2005, The Journal of rheumatology.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Yoshimasa Tanaka, T. Okazaki, T. Honjo, 2002, Proceedings of the National Academy of Sciences of the United States of America.

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

G. Freeman, T. Okazaki, T. Honjo, 2001, Nature Immunology.

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

G. Freeman, M. Byrne, T. Okazaki, 2000, The Journal of experimental medicine.

Cancer immunotherapies targeting the PD-1 signaling pathway

Tasuku Honjo, Yoshiko Iwai, T. Honjo, 2017, Journal of Biomedical Science.

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.

F. Tanaka, Yoshiko Iwai, K. Yoneda, 2018, Immunology letters.

IκBζ regulates TH17 development by cooperating with ROR nuclear receptors

Hiroshi Takayanagi, Yoshiko Iwai, Kazuhiro Aoki, 2010, Nature.

Rap1b Promotes Notch-Signal-Mediated Hematopoietic Stem Cell Development by Enhancing Integrin-Mediated Cell Adhesion.

Hiromi Hirata, N. Mochizuki, S. Fukuhara, 2019, Developmental cell.

PD-L 1 / B 7 H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor ( TCR ) Transgenic CD 8 T Cells

T. Honjo, C. Blank, M. Spiotto, 2004 .

Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung

F. Tanaka, Yoshiko Iwai, Naoko Imanishi, 2018, Journal of surgical oncology.

Expression of BAF57 in ovarian cancer cells and drug sensitivity

H. Izumi, K. Nishio, T. Hachisuga, 2015, Cancer science.

An IFN-γ-IL-18 Signaling Loop Accelerates Memory CD8+ T Cell Proliferation

R. Steinman, Yoshiko Iwai, H. Hemmi, 2008, PloS one.

IκBζ regulates TH17 development by cooperating with ROR nuclear receptors

S. Akira, T. Morio, Masahiro Yamamoto, 2010, Nature.

In Vivo Imaging Joints Uncovers the Pathogenesis of Inflammatory Arthritis

Yoshiko Iwai, Y. Miyabe, 2020, Nihon Ika Daigaku Igakkai Zasshi.